Sat, Jul 26, 2014, 7:55 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • terry_insm terry_insm May 6, 2013 7:51 PM Flag

    Why Cannacord and Wedbush agree on $12

    This morning Goldman said the S&P 500 is now trading near fair value based on several methodologies.
    The explosive biotech rally of the last 2 years will end with a sector rotation (which I dont pretend to know when), but one thing is for sure.- Sectors ,all sectors are ultimately affected by the S&P

    Insmed will have no profits for years( 3 is BCS),also watch for the coming dilution.- it will happen unless they partner.

    Say nothing of competing with pharma powerhouses Novartis and Gilead,Cannacord and Wedbush agree
    on the orphan for CF- it will not surpass 100 Million. (Wedbush 65-75 M 2018)at full market penetration.
    (btw- that is a strong 25-30 % of the total market.)

    Ultimately the results may change things - to speculate above what is known is the height of folly in biotech.
    Now I just put our resident clowns on ignore and I see $250 off label and I dont have to even guess which idiot it was...anyway
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
17.50-0.11(-0.62%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.